Sapient Capital LLC Sells 8,705 Shares of AbbVie Inc. $ABBV

Sapient Capital LLC lowered its stake in AbbVie Inc. (NYSE:ABBV) by 4.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 196,236 shares of the company’s stock after selling 8,705 shares during the quarter. AbbVie comprises approximately 0.6% of Sapient Capital LLC’s holdings, making the stock its 22nd largest holding. Sapient Capital LLC’s holdings in AbbVie were worth $49,381,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Litman Gregory Wealth Management LLC bought a new stake in shares of AbbVie in the fourth quarter worth about $28,000. Imprint Wealth LLC boosted its stake in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the last quarter. IFC & Insurance Marketing Inc. purchased a new position in AbbVie during the 4th quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID increased its stake in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC increased its stake in AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Down 0.1%

NYSE ABBV opened at $245.82 on Monday. The company has a fifty day moving average of $241.96 and a two-hundred day moving average of $225.04. The firm has a market capitalization of $434.31 billion, a price-to-earnings ratio of 69.44, a PEG ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is presently 195.48%.

Analysts Set New Price Targets

A number of research firms recently weighed in on ABBV. Barclays raised their target price on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Morgan Stanley reaffirmed an “overweight” rating and set a $296.00 price target on shares of AbbVie in a research note on Monday, August 3rd. HSBC reissued a “buy” rating and issued a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Evercore set a $235.00 target price on shares of AbbVie in a research report on Friday, May 15th. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $275.70.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.